Product Description
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Altana
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Other|Stargardt Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FMumps-KMB17-I-IMB-CAMS | P2 |
Not yet recruiting |
Other |
2021-12-31 |
|
| 2018-001496-20 | P2 |
Active, not recruiting |
Stargardt Disease |
2021-11-14 |